Scientific deep-dive

A Drug to Protect Muscle

A myostatin-targeting antibody tested alongside tirzepatide was well tolerated and, the authors conclude, effective at preserving lean mass. In its one trial, people on it lost 1.9 kg less lean mass than on placebo.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·1 citation

If losing lean tissue is the main objection to these drugs, the pharmaceutical answer is a second drug that blocks it. Apitegromab targets myostatin, the signal that limits muscle growth, and a randomized trial tested it alongside tirzepatide. The authors conclude it was well tolerated and effective in preserving lean mass.[1]

What was tested

It was a double-blind, placebo-controlled proof-of-concept study with 51 participants per arm, all receiving tirzepatide. Two measures rose over time and plateaued at around 16 weeks: apitegromab concentrations and total latent myostatin, the marker showing the drug is doing what it is designed to do.[1]

Adverse events occurred in 76% of apitegromab participants and 71% on placebo. Serious adverse events were balanced: one participant in each arm.[1]

The size of the effect: 1.9 kg less lean mass lost than on placebo at week 24, with similar total weight loss in both groups. The authors describe that as a 54.9% retention of lean mass relative to placebo. Note the interval: the paper reports an 80% confidence interval (1.2 to 2.7 kg), narrower than the usual 95%, which suits a proof-of-concept trial but makes the result look more precise than it is.[1] Magnitudes are easy to lose in summaries: the bimagrumab abstract reported only total weight. A percentage can hide it too: a compounded semaglutide study reported a rising lean proportion, yet its own numbers put 35% of the weight lost in lean tissue.

Why a drug, when training already works

Resistance training is the intervention with randomized evidence for changing what you lose. In a meta-analysis of 20 trials it cut the lean share of weight lost from roughly a quarter to 17.5% (covered in lean mass, drug versus dieting). It costs nothing and has no side effects worth the name. Creatine, the supplement most often added to it, has never been tested in people taking a GLP-1.

So why develop a drug? Some people cannot train, because of disability, joint disease, or the sheer difficulty of starting when mobility is already limited. People living with a spinal cord injury are the clearest case, and almost no obesity research enrolls them. And adherence to exercise is famously poor, which is precisely the problem a drug solves. A pharmacological option is less a substitute for training than a fallback for people for whom training is not available.

The intervention with the best evidence is free. The one attracting investment is not.

And whether mass is the right target at all

Every drug in this category aims at lean mass, because mass is what a scan measures. What people need is function, and the two do not move together as reliably as the framing suggests.

We have covered a study where psoas muscle volume fell 9.3% while chair-rise time and walking speed both improved. In another, handgrip strength rose 4.5 kg over a year while sarcopenic obesity fell from 49% to 33% (see handgrip strength). A muscle-preservation drug that protected mass without improving function would be treating the measurement rather than the problem.

None of this argues against developing one. It does argue for insisting that the phase 3 program measures what people can do, and not only what the scan says.

Nobody can obtain this. It is a proof-of-concept study of an unapproved drug, given by injection alongside another injection, years from any pharmacy. As with bimagrumab, anything sold under this name today is not what it claims to be. What can be bought for the same worry rests on less: MK-677 has a seven-day trial in eight people that measured nitrogen balance, not muscle. See what cannot legally be compounded.

Frequently Asked Questions

Two are in development. Apitegromab targets myostatin and was tested alongside tirzepatide in a proof-of-concept trial of 51 participants per arm; the authors report it was well tolerated and effective at preserving lean mass.
At week 24, people on apitegromab lost 1.9 kg less lean mass than those on placebo, with similar total weight loss. The authors call that a 54.9% retention of lean mass. It is one proof-of-concept trial of 102 people, reported with an 80% confidence interval.
For most people that is the better answer. Resistance training has randomized evidence and cut the lean share of weight lost from about a quarter to 17.5%. A drug matters for people who cannot train because of disability or joint disease, and for the very common problem of exercise adherence.
Not necessarily, and that is the open question. Studies have found muscle volume falling while walking speed and grip strength improved. A drug that protected the scan measurement without improving function would be treating the wrong endpoint.
No. It is an unapproved drug at proof-of-concept stage, given by injection alongside another injection, and years from a pharmacy at best.

References

  1. 1.Pratley RE, Denham DS, Trivedi R, et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled trial Nature Medicine. 2026. PMID: 42260100.

Bimagrumab Plus Semaglutide: The Muscle Question

The combination lost 17.8 kg at 48 weeks against 14.2 kg for semaglutide alone. But bimagrumab exists to change what you lose, and the published summary reports only how much.

6 min read

Eloralintide and Petrelintide: The Amylin-Only Drugs in Phase 3

In phase 2, Lilly's eloralintide cut weight by about 20% at 48 weeks; Zealand and Roche's petrelintide up to 10.7% at 42 weeks with little vomiting. Both are in phase 3, due to finish in 2028. Neither is approved.

10 min read

Elecoglipron: A Second Oral GLP-1 Pill in Phase 2

Weight reductions from 2.6% to 10.5% at 26 weeks depending on dose, against 0.6% on placebo. 93% completed the study but only 75% completed the assigned treatment.

5 min read

Cagrilintide: What the Evidence Shows, and Why You Can't Buy It

Cagrilintide, Novo Nordisk's amylin analog, produced 11.8% weight loss on its own at 68 weeks, less than semaglutide. It is not approved, cannot be compounded, and FDA has warned companies selling it.

9 min read

MariTide (Maridebart Cafraglutide): What the Evidence Shows

Amgen's monthly MariTide cut weight 12.3% to 16.2% at 52 weeks in phase 2, against 2.5% on placebo. It blocks GIP where tirzepatide activates it. Side effects, the MARITIME phase 3 trials, and why it cannot be bought yet.

10 min read

CagriSema Beat Semaglutide. By How Much?

CagriSema was statistically superior to semaglutide on HbA1c in type 2 diabetes. The margin was 0.16 percentage points, and adverse events were higher: 86.9% against 81.2%.

5 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

MyDrHank

An oral route if you will not self-inject

8.2

bmiMD

Starting below a standard dose, with microdose tiers

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →